

Council Authors' representative Candidate Statement

Family name (surname):

Garegnani

First name(s):

Luis Ignacio

Today's date:

Monday 23rd August

Role in a Cochrane Group:

Deputy Director - Cochrane Associate Centre

Please state:

1. Why you wish to run for a position on the Cochrane Council?

During my fellowship in systematic reviews at Istituto Universitario Hospital Italiano Cochrane Associate Centre I was able to expand my knowledge related to Cochrane functioning and organization, while working on several projects, some of which I lead, with researchers from all over the world, advocating for evidence-informed decision-making in healthcare. I believe that joining the Cochrane Council will allow me to continue my commitment with the organization and its mission, providing input and raising matters that eventually could translate into an improved and efficient workflow to complete our goals.

I believe authors should be provided of all the support they deemed necessary from the organization to perform their research, including all kind of methodological, material, technical or financial resources, especially in priority topic reviews. Furthermore, authors from non-English speaking countries or those from low and middle income countries should be especially supported in order to shorten the gap with researchers from English-speaking countries or high income countries and favouring equity. They should also be recognized for their work and should be encouraged to continue.

2. What skills, experiences or qualities you would bring to the Council

I believe I have deep knowledge about research methods and health technologies assessments, always keeping a critical approach and a very flexible and creative mind for problems' solving. I also consider my self a highly organized person. As I continue my clinical work as a Respiratory Therapist, I believe I can provide the Council with input on clinician's concerns related to available information and the need for further research to assist decision-making, considering all stakeholders possible scopes. I can share with the Council my experience related to the production of Cochrane reviews as an author, the different issues I was able to identify with the tools available for evidence synthesis in order to work on a solution together. Luckily, if I am elected for the Authors representative position, I will be able to explore other authors' experiences and concerns and share them with the Council. For example, at the protocol stage of one of my projects, we received the exact same feedback from a peer reviewer in two separate rounds of feedback, which led me to think we had done something wrong modifying our protocol while addressing the reviewers comments. We contacted the review group and, fortunately, we were able to identify that our responses did not get to the peer reviewer completely. This same project required further discussion between the peer reviewer, the CRG and the authors team to reach consensus regarding the review title, with several proposals coming and going from all parties, until we all agreed on one title that fitted all our concerns and reflected precisely the research question we had in mind.

3. List the Cochrane Review(s) on which you have an Author role

Protocols

Garegnani L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing respiratory syncytial virus (RSV) infection in children. Cochrane Libr 2020. <https://doi.org/10.1002/14651858.cd013757>.

Garegnani L, Hyland M, Roson Rodriguez P, Escobar Liquitay CM, Quinlivan R, Franco JVA. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline. Cochrane Libr 2020. <https://doi.org/10.1002/14651858.cd013720>.

Roson Rodriguez P, Franco JVA, Garegnani L, Arancibia M, Escobar Liquitay CM, Mohammad HA. Transitional discharge interventions for people with serious mental illness. Cochrane Libr 2019. <https://doi.org/10.1002/14651858.cd009788.pub2>.

Reviews

Garegnani L, Franco JV, Ciapponi A, Garrote V, Vietto V, Portillo Medina SA. Ventriculo-peritoneal shunting devices for hydrocephalus. Cochrane Database Syst Rev 2020;6:CD012726.

Franco JV, Garegnani L, Escobar Liquitay CM, Borofsky M, Dahm P. Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2021;6:CD004135.

Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, Young S, Goltzarian J, Veroniki AA, Garegnani L, Dahm P. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD013656. DOI: 10.1002/14651858.CD013656.pub2.

4. Acknowledge that you are aware of the commitment required to participate **YES**

Date of the application: Monday 23rd August